The rationale for mTOR inhibition in epithelial ovarian cancer

Bibliography

• Kelland LR. Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs 2005;10:413-24
   PubMedGoogle Scholar
• Berek JS, Bertelsen K, du BA, Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999;10(Suppl 1):87-92
   PubMed Web of Science ®Google Scholar
• Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994;55:S97-107
   PubMed Web of Science ®Google Scholar
• Helleman J, Jansen MP, Span PN, Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006;118:1963-71
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71
   PubMed Web of Science ®Google Scholar
• Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
   PubMed Web of Science ®Google Scholar
• Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007;25:2894-901
   PubMed Web of Science ®Google Scholar
• Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6
   PubMed Web of Science ®Google Scholar
• Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation kaposi's sarcoma. Transplantation 2004;77:760-2
   PubMed Web of Science ®Google Scholar
• Campistol JM, Eris J, Oberbauer R, Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9
   PubMed Web of Science ®Google Scholar
• Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004;30:628-33
   PubMed Web of Science ®Google Scholar
• Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004;77:1777-82
   PubMed Web of Science ®Google Scholar
• Kahan BD, Yakupoglu YK, Schoenberg L, Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005;80:749-58
   PubMed Web of Science ®Google Scholar
• Kauffman HM, Cherikh WS, Cheng Y, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9
   PubMed Web of Science ®Google Scholar
• Luan FL, Hojo M, Maluccio M, Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72
   PubMed Web of Science ®Google Scholar
• Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004;18:446-9
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46
   PubMed Web of Science ®Google Scholar
• Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83
   PubMed Web of Science ®Google Scholar
• Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005;10:479-98
   PubMed Web of Science ®Google Scholar
• Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-22
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34
   PubMed Web of Science ®Google Scholar
• Roiron C, Sanchez P, Bouzamondo A, Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92:641-9
   PubMed Web of Science ®Google Scholar
• Averous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene 2006;25:6423-35
   PubMed Web of Science ®Google Scholar
• Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 1994;91:12574-8
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006;25:6347-60
   PubMed Web of Science ®Google Scholar
• Jefferies HB, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the 'polypyrimidine tract' mRNA family. Proc Natl Acad Sci USA 1994;91:4441-5
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Maurer MJ, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304
   PubMed Web of Science ®Google Scholar
• Iwenofu OH, Lackman RD, Staddon AP, Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008;21:231-7
   PubMed Web of Science ®Google Scholar
• Altomare DA, Wang HQ, Skele KL, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;23:5853-7
   PubMed Web of Science ®Google Scholar
• Sahin F, Kannangai R, Adegbola O, mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10:8421-5
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101
   PubMed Web of Science ®Google Scholar
• Tabernero J, Rojo F, Burris H, A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol 2005;23(Suppl 16):3007
   Google Scholar
• Gao N, Flynn DC, Zhang Z, G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004;287:C281-91
   PubMed Web of Science ®Google Scholar
• Gao N, Nester RA, Sarkar MA. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol 2004;196:124-35
   PubMed Web of Science ®Google Scholar
• Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006;102:292-9
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Altomare DA, Cheung M, RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-70
   PubMed Web of Science ®Google Scholar
• Aguirre D, Boya P, Bellet D, Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004;9:797-805
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Altomare DA, Connolly DC, RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007;67:2408-13
   PubMed Web of Science ®Google Scholar
• Jiang H, Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl 1):405-12
   PubMed Web of Science ®Google Scholar
• Huynh H, Teo CC, Soo KC. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther 2007;6:2959-66
   PubMed Web of Science ®Google Scholar
• Philp AJ, Campbell IG, Leet C, The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-9
   PubMed Web of Science ®Google Scholar
• Shayesteh L, Lu Y, Kuo WL, PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102
   PubMed Web of Science ®Google Scholar
• Bellacosa A, de Feo D, Godwin AK, Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5
   PubMed Web of Science ®Google Scholar
• Cheng JQ, Godwin AK, Bellacosa A, AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71
   PubMed Web of Science ®Google Scholar
• Saito M, Okamoto A, Kohno T, Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 2000;85:160-5
   PubMed Web of Science ®Google Scholar
• Kurose K, Zhou XP, Araki T, Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097-106
   PubMed Web of Science ®Google Scholar
• Sun M, Wang G, Paciga JE, AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-7
   PubMed Web of Science ®Google Scholar
• Castellvi J, Garcia A, Rojo F, Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006;107:1801-11
   PubMed Web of Science ®Google Scholar
• Noske A, Lindenberg JL, Darb-Esfahani S, Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 2008;20:1409-17
   PubMed Web of Science ®Google Scholar
• Trinh XB, Tjalma WA, Vermeulen PB, The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009;100:971-8
   PubMed Web of Science ®Google Scholar
• NCT00429793, NCT00408655, NCT00703170, NCT00703625, NCT00926107 and NCT00523432. Available from: www.clinicaltrials.gov (Last accessed 4 August 2009)
   Google Scholar
• Oza AM, Kollmannsberger C, NCIC Clinical Trials Group, etal. Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179. J Clin Oncol2009;27:15s(suppl);[abstract 3558]
   Google Scholar
• Ikezoe T, Nishioka C, Bandobashi K, Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2007;31:673-82
   PubMed Web of Science ®Google Scholar
• Matei D. Novel agents in ovarian cancer. Expert Opin Investig Drugs 2007;16:1227-39
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Hezel AF, Abrams T, Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-8
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357-61
   PubMed Web of Science ®Google Scholar
• Duran I, Kortmansky J, Singh D, A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54
   PubMed Web of Science ®Google Scholar
• Chan S, Scheulen ME, Johnston S, Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T, CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8
   PubMed Web of Science ®Google Scholar